VICTOR-E4: vicriviroc plus optimized antiretroviral therapy in treatment-experienced HIV infection

Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Vicriviroc + optimized background therapy with Placebo + optimized background therapy (2 arms). Primary endpoints: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48 and Clinically significant laboratory abnormalities. Started Jun 2007; status: terminated.